InsiderClue
← All stocks

ENANTA PHARMACEUTICALS INC

ENTA Net selling
CIK 0001177648 #3326 in the set updated 17 Sep 2026
Bought (12 mo)
$0.00
out of their own pocket, the only kind of buying there is
Sold (12 mo)
$183.17K
$0.00 on a plan · $0.00 straight out of an exercise
Sold at will
$183.17K
9 of 9 sales
Net
−$183.17K
−$183.17K against sales at will

By person

9 insiders · 9 transactions
Insider
Role
Bought
Sold
Net
Holding
Of company
Worth
Change
Luly Jay R.
President and CEO
—
$67.49K (1)
−$67.49K
871,871
2.99%
$12.41M
+7.6%
Or Yat Sun
Chief Scientific Officer
—
$34.01K (1)
−$34.01K
374,854
1.29%
$5.33M
+0.4%
Kieffer Tara Lynn
Chief Product Strategy Officer
—
$29.97K (1)
−$29.97K
33,925
0.1165%
$482.75K
+4.9%
Luu Brendan
Chief Business Officer
—
$19.84K (1)
−$19.84K
41,634
0.1429%
$592.45K
+6.5%
Trout Harry R. III
See Remarks
—
$13.02K (2)
−$13.02K
16,348
0.0561%
$232.63K
+49.8%
Rottinghaus Scott T.
Chief Medical Officer
—
$11.36K (1)
−$11.36K
23,787
0.0817%
$338.49K
+26.6%
Capps Kathleen S.
See Remarks
—
$7.49K (2)
−$7.49K
8,377
0.0288%
$119.20K
+43.7%
MELLETT PAUL J
Chief Fin. & Admin Officer
—
—
—
95,884
0.3292%
$1.36M
0.0%
Kowalsky Matthew Paul
Chief Legal Officer
—
—
—
3,591
0.0123%
$51.10K
—

Individual transactions

9
Insider
Date
Role
Action
Shares
Price
Amount
Luly Jay R.
5 Dec 2025
President and CEO
Sell
4,743
$14.23
$67.49K
Or Yat Sun
5 Dec 2025
Chief Scientific Officer
Sell
2,390
$14.23
$34.01K
Kieffer Tara Lynn
5 Dec 2025
Chief Product Strategy Officer
Sell
2,106
$14.23
$29.97K
Luu Brendan
5 Dec 2025
Chief Business Officer
Sell
1,394
$14.23
$19.84K
Rottinghaus Scott T.
5 Dec 2025
Chief Medical Officer
Sell
798
$14.23
$11.36K
Trout Harry R. III
5 Dec 2025
See Remarks
Sell
542
$14.23
$7.71K
Capps Kathleen S.
5 Dec 2025
See Remarks
Sell
323
$14.23
$4.60K
Trout Harry R. III
2 Dec 2025
See Remarks
Sell
380
$13.96
$5.30K
Capps Kathleen S.
2 Dec 2025
See Remarks
Sell
207
$13.96
$2.89K
Show all 9 transactions →

What was left out

Form 4 filings counted 34
Amendments (4/A) skipped 0
Filings about a different issuer 0
Unreadable filings 0
Joint filings 0
Sales on a Rule 10b5-1 plan 0
Sales straight out of an exercise 0
Sales at will 9
Transactions with no price 0
Shares from compensation/vesting 88,936
History held since 29 Sep 2016